Inhibikase Therapeutics, Inc. (NYSE:IKT - Get Free Report) shares shot up 4.9% during trading on Monday . The company traded as high as $2.40 and last traded at $2.36. 175,997 shares were traded during mid-day trading, a decline of 20% from the average session volume of 220,970 shares. The stock had previously closed at $2.25.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright downgraded Inhibikase Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th.
View Our Latest Stock Analysis on Inhibikase Therapeutics
Inhibikase Therapeutics Trading Up 4.9 %
The business's 50 day simple moving average is $2.51 and its two-hundred day simple moving average is $2.33. The firm has a market capitalization of $163.69 million, a PE ratio of -0.88 and a beta of 1.04.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. Jefferies Financial Group Inc. purchased a new stake in Inhibikase Therapeutics in the fourth quarter worth about $48,000. Alpine Global Management LLC bought a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at approximately $48,000. Soleus Capital Management L.P. purchased a new stake in Inhibikase Therapeutics in the 4th quarter worth approximately $20,556,000. Squarepoint Ops LLC bought a new stake in Inhibikase Therapeutics during the 4th quarter worth approximately $92,000. Finally, Stonepine Capital Management LLC purchased a new position in Inhibikase Therapeutics during the fourth quarter valued at approximately $3,680,000. Hedge funds and other institutional investors own 3.81% of the company's stock.
About Inhibikase Therapeutics
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
